Design of a minimized cyclic tetrapeptide that neutralizes bacterial endotoxins.
Septic shock is a leading cause of mortality in intensive care patients, and no specific drugs are as yet available for its treatment. Therefore, new leads are required in order to increase the number of active molecules that may develop into efficacious and safe LPS-neutralizing molecules during pre-clinical stages. We used peptides, derived from the binding regions of known LPS-binding proteins, as scaffolds to introduce modifications at the amino acid level. Structure-activity relationship studies have shown that these modifications generate highly active peptides. Thus, from a bioactive peptide with an initial 16 amino acid residues, a tetrapeptide sequence was determined. After inserting this sequence in a Cys cyclic peptide, it showed the same biological activity as the parent peptide. This sequence could provide the basis for the design of small molecules with LPS-binding properties.
Mora
Puig
P
Department of Medicinal Chemistry, Centro de Investigaciones Principe Felipe, Avda Autopista del Saler, 16 46013-València, Spain.
Mas-Moruno
Carlos
C
Tamborero
Silvia
S
Cruz
Luis J
LJ
Pérez-Payá
Enrique
E
Albericio
Fernando
F
D000595:Amino Acid Sequence; D000818:Animals; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors*; D015195:Drug Design; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D006801:Humans; D066298:In Vitro Techniques; D008033:Limulus Test; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D015394:Molecular Structure; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D010449:Peptide Mapping; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D012772:Shock, Septic / Q000188:drug therapy
D001427:Bacterial Toxins; D004731:Endotoxins; C499147:LALF-14 peptide; D008070:Lipopolysaccharides; D009842:Oligopeptides; D010456:Peptides, Cyclic; C440499:lipopolysaccharide, Escherichia coli O111 B4